Feed / BCDA

BioCardia, Inc.

BCDA

Healthcare · 1.13 +13.0% today

Partial group confirmationMarket checked 25 Aug, 15:55 GMT-4

Jodie situation report

BioCardia, Inc.'s move is being confirmed by its market group.

BCDA accounts for 10.3% of the group's measured movement across 3.7 effective names. raw member direction is mixed; 5 of 8 SPY-adjusted paths align to the upside. Capital-flow agreement is 18%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#3 of 8 by movement share
Group movement share10.3%Absolute path energy—not portfolio weight
Relative path+0.82%aligned
Effective breadth3.7 / 8concentrated
Relative alignment5/8upside path · 2 counter-moving
Capital-flow agreement18%not yet clean
SEQUENCE READ

CLNN, PACB moved materially before BCDA. BCDA crossed its material path threshold at 15:35 ET. DNA, RXRX, TEM followed.

EVIDENCE COVERAGE

5 of 8 members in Gene Therapies are active. 0 of 8 disclosed connections are confirming.

What would change this read
  • Participation spreads to CLNN, PACB, VERU.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as PRTA begins moving with the group.

Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.

Watch this read

Who this business touches

The relationships behind BCDA

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

AZNAstraZeneca PLCcompetitorMar 24, 2026 ▾

“The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market, including AstraZeneca, Bayer, Blue Rock Therapeutics, Bristol-Myers Squibb, Lisata Therapeutics, Capricor Therapeutics, Celixir, Cel…”

CAPRCapricor Therapeutics, Inc.competitorMar 24, 2026 ▾

“The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market, including AstraZeneca, Bayer, Blue Rock Therapeutics, Bristol-Myers Squibb, Lisata Therapeutics, Capricor Therapeutics, Celixir, Cel…”

LSTAFiling-linked namecompetitorMar 24, 2026 ▾

“The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market, including AstraZeneca, Bayer, Blue Rock Therapeutics, Bristol-Myers Squibb, Lisata Therapeutics, Capricor Therapeutics, Celixir, Cel…”

Filing peers

CAPRPMICDNA

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 7 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

BCDA is currently a Leader in the organic co-movement group Gene Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.